Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
Oxford Biomedica, a leading gene and cell therapy group, has signed a one-year clinical and commercial supply deal with AstraZeneca for a potential Covid-19 vaccine. The agreement relates to the adenovirus vector-based vaccine candidate AZD1222, which entered clinical trials at multiple sites in the UK recently. Oxford...